Olerup SSP extends its product portfolio through a new exclusive sales agreement
LinkMed’s transplantation company, Olerup SSP, has signed an exclusive sales agreement with the American company Biotium for their product GelRed™. The sales agreements gives Olerup SSP the exclusive rights to sell GelRed™ to the HLA typing market. GelRed™ is an environmentally safe and ultrasensitive fluorescent nucleic acid gel stains designed to replace the highly toxic ethidium bromide (EtBr).
Developed by Biotium, GelRed™ is superior to EtBr and other EtBr alternatives by having a combination of low toxicity, high sensitivity and exceptional stability. GelRed™ is a sensitive, stable and environmentally safe fluorescent nucleic acid dye designed to replace the toxic ethidium bromide for staining dsDNA, ssDNA or RNA in agarose gels or polyacrylamide gels.
GelRed™ is impermeable to latex gloves and cell membranes. Furthermore, GelRed™ is noncytotoxic and nonmutagenic at concentrations well above the working concentrations used in gel staining. Another great advantage is the easy disposal of GelRed™ down to regular drain or in regular trash- because the substance is not classified as hazardous waste.
“We have been working with Biotium for several months, testing their product GelRed in our lab and we are very satisfied with the result. Other staining agents such as EtBr are so toxic that women expecting are recommended not to work with it. Signing an exclusive agreement with Biotium and offering GelRed with our HLA typing kits will give us a competitive advantage” says Assoc. Prof. Olle Olerup, CEO Olerup SSP.
For more information about GelRed™, please visit www.biotium.com
For more information about Olerup SSP, please visit www.olerup-ssp.com
For more information please contact:
Olle Olerup, CEO Olerup SSP, email: olle.olerup@olerup.com
Lars Öqvist, Head of Sales and Marketing, Olerup SSP and AbSorber email: lars.oqvist@absorber.se
Or visit www.linkmed.se
LinkMed has two business areas, a commercial transplantation sector business with two subsidiaries and a venture portfolio comprising life science companies. The venture companies, all of which are associated companies, consist of four companies in drug development and biotechnology and six companies in diagnostics and medical technology. LinkMed is listed on NASDAQ OMX Stockholm, in the Small Cap sector (ticker symbol: LMED).
Tags: